Semaglutide is widely recognised as the active medicine used in Ozempic and Wegovy. It is prescribed to help people with type 2 diabetes control blood glucose, and it is also used to support weight loss.
Researchers are now exploring a broader possibility: whether this same drug might influence the way the body grows older.
A recent study offers an early signal that it could. It does not demonstrate that semaglutide extends lifespan, and it does not show that it makes anyone younger.
What it does indicate is that semaglutide may dampen certain internal, biological features that are linked with ageing.
What aging really means
Age is often treated as a simple tally of years lived-40, 50, or 70. In practice, the body does not always match that number.
Two people with the same chronological age can differ markedly in what is happening at the cellular level.
One may carry higher inflammation, more fat stored around the organs, and greater disease risk. Another might have healthier blood vessels, a more efficient metabolism, and lower inflammatory activity.
This gap is commonly described as biological age-the idea of how old the body appears “on the inside”.
To estimate biological age, scientists can examine small chemical tags on DNA that shift as people get older. Those shifts are used to build tools known as epigenetic clocks.
Epigenetic clocks are designed to provide indications of how quickly the body may be ageing.
HIV can accelerate aging
In this research, scientists studied adults living with HIV who also had excess deep abdominal fat.
This particular fat-visceral fat-accumulates around internal organs. Compared with fat stored under the skin, it is considered more damaging because it is associated with inflammation, heart disease, diabetes, and faster ageing.
Even when HIV is well managed and the virus remains controlled, people living with HIV can still display signs consistent with accelerated biological ageing. Ongoing inflammation and metabolic strain may persist over the long term.
“People with HIV often experience accelerated aging, even if it is well-controlled with antiretroviral therapy,” said Dr. Michael Corley, associate professor at UC San Diego School of Medicine and the study’s first author.
That is why this population was especially relevant to the study: if ageing-related signals are already more pronounced, it can be easier to detect whether an intervention shifts them.
Testing the effects of semaglutide
The clinical trial ran for 32 weeks. One group received semaglutide once per week, while the other group was given a placebo that resembled the treatment but contained no active drug.
The trial was originally designed to assess body fat, focusing on whether semaglutide could change fat stored around the organs and elsewhere in the body.
Afterwards, researchers analysed stored blood samples to evaluate markers linked with ageing. They examined DNA patterns and applied 17 different epigenetic clocks to estimate biological ageing.
Using multiple clocks provided a wider perspective, rather than depending on a single measure of how the body might be ageing.
Signs of slower aging
Across several of the epigenetic clocks, participants who received semaglutide appeared to show slower biological ageing than those who received placebo.
One of the clocks, DunedinPACE, indicated that during the study period the semaglutide group aged about 9 percent more slowly.
Additional clocks also moved in a favourable direction, particularly those related to inflammation, metabolism, and cardiovascular health.
These results do not imply that time was reversed; rather, they reflect blood-based changes that scientists associate with a slower pace of ageing.
The team also tested whether the findings could be explained simply by shifts in the mix of blood cell types. They did not find evidence for that, which strengthens the interest in the signal they observed.
Fat may be the key
A plausible explanation is semaglutide’s ability to reduce visceral fat.
Visceral fat is more than stored energy. It can release signals that amplify inflammation throughout the body, potentially placing long-term strain on organs and contributing to age-related harm.
By lowering levels of this organ-surrounding fat, semaglutide may also reduce inflammation that is linked with faster biological ageing.
“Emerging data also suggest that GLP-1 drugs may reprogram certain cells in different organs, which could help explain why we see effects across multiple aging clocks,” Corley said.
The study also reported improved ageing signals connected to a range of bodily systems, including the brain, heart, liver, kidneys, blood, metabolism, and inflammation.
At the same time, these observations were based on blood markers rather than direct measures of ageing within specific organs.
Significance of the research
Ageing is the largest risk factor for many major conditions, including heart disease, dementia, diabetes, and kidney disease.
As a result, scientists are increasingly investigating whether it is possible to slow the biological processes that raise the likelihood of these illnesses.
Semaglutide draws attention because it already influences several relevant pathways, including body weight, blood glucose, inflammation, and metabolism.
This study adds to that picture by suggesting an association with molecular indicators tied to ageing.
“Many of the biological processes we study in HIV are also central to aging in the general population,” Corley said.
“Because these processes can emerge earlier or be more pronounced in people with HIV, this community can help us identify interventions that may improve healthspan more broadly.”
Healthspan refers to the years a person spends in good health. It is not only about living longer, but also about remaining healthier for a greater portion of life.
Important questions remain
The research was limited in size: 84 people were included in the final ageing analysis. It also ran for less than a year, so it is unclear whether the observed effects would persist over longer periods.
In addition, the participants were people living with HIV who had excess visceral fat, meaning the findings may not generalise to everyone.
It is also important that the clocks did not all shift. Some showed minimal change or no clear effect.
This pattern suggests semaglutide may influence certain aspects of ageing-especially those connected with fat, inflammation, and metabolism-without affecting every ageing pathway.
Future research directions
Based on this single study, semaglutide should not be described as an anti-ageing medicine. At present, it remains used for established medical indications such as diabetes treatment and weight management.
“We are not saying that semaglutide reverses aging or makes people younger,” Corley said.
“What we are seeing is a signal that it may slow some of the biological processes associated with aging.”
“With newer GLP-1-based therapies now emerging, the field has an opportunity to test whether different drugs in this class have distinct effects on aging biology and to identify which patients may benefit most.”
For now, the results provide a promising lead: a drug best known for weight loss may also interact with biological systems linked to ageing.
The next stage is to examine these questions in larger studies, over longer periods, and across a wider range of people.
Comments
No comments yet. Be the first to comment!
Leave a Comment